Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W9WF
|
||||
| Former ID |
DAP000623
|
||||
| Drug Name |
Ketoprofen
|
||||
| Synonyms |
Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-3-Benzoyl-alpha-methylbenzeneacetic acid; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-BENZOYL-ALPHA-METHYLBENZENEACETIC ACID; 3-Benzoylhydratropic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Rheumatold arthritis; Pain [ICD9: 338, 714,780; ICD10:M05-M06, R52, G89] | Approved | [1], [2] | ||
| Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Phase 3 | [3], [4] | |||
| Therapeutic Class |
Analgesics
|
||||
| Company |
ProEthic Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H14O3
|
||||
| InChI |
InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
|
||||
| InChIKey |
DKYWVDODHFEZIM-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 22071-15-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
4853, 857801, 5316933, 7847200, 7979680, 8149782, 8152423, 10321584, 10513923, 11335773, 11361012, 11364203, 11366765, 11369327, 11372636, 11373574, 11377489, 11461984, 11466247, 11467367, 11484688, 11485894, 11488772, 11491294, 11491843, 11495123, 11532908, 11533518, 15122326, 17405247, 24278504, 24860779, 24896217, 26612243, 26679814, 26747548, 26747549, 29222944, 46505715, 47216761, 47365167, 47588981, 47588982, 47588983, 47662267, 47736456, 47810738, 48184977, 48413934, 49698784
|
||||
| ChEBI ID |
ChEBI:6128
|
||||
| SuperDrug ATC ID |
M01AE03; M02AA10
|
||||
| SuperDrug CAS ID |
cas=022071154
|
||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [5] | |
| BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
| Aspirin triggered resolvin D biosynthesis | |||||
| C20 prostanoid biosynthesis | |||||
| Aspirin triggered resolvin E biosynthesis | |||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancer | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TSH Signaling Pathway | |||||
| IL4 Signaling Pathway | |||||
| TGF_beta_Receptor Signaling Pathway | |||||
| IL5 Signaling Pathway | |||||
| PANTHER Pathway | Endothelin signaling pathway | ||||
| Inflammation mediated by chemokine and cytokine signaling pathway | |||||
| Toll receptor signaling pathway | |||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | ||||
| S1P1 pathway | |||||
| C-MYB transcription factor network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| Calcium signaling in the CD4+ TCR pathway | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| Arachidonic acid metabolism | |||||
| Aryl Hydrocarbon Receptor | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Spinal Cord Injury | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4795). | ||||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073516. | ||||
| REF 3 | Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9. | ||||
| REF 4 | Synthesis and biological testing of Acyl-CoA-ketoprofen conjugates as selective irreversible inhibitors of COX-2. Bioorg Med Chem. 2002 Mar;10(3):753-7. | ||||
| REF 5 | Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62. Epub 2007 Jun 25. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.